Skip to main content
    P

    Pharvaris BV (PHVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.28
    -0.16 (-0.49%)

    Market Cap: $2.36B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Pharvaris BV (PHVS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pharvaris BV (PHVS) has a market cap of $2.36B. Its share count is up 12.96% from a year earlier.

    Total Valuation

    Market Cap$2.36B
    Latest price (Nov 17, 2026)$32.28

    Key Dates

    The next earnings report is expected on Apr 5, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateApr 5, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.31% in the quarter ended Sep 30, 2026 and grew 14.05% a year over 2 years.

    Shares Outstanding70.33M
    Shares Change (YoY)+12.96%
    Shares Change (QoQ)+3.31%
    Share Count Growth (2Y CAGR)+14.05%

    Price Statistics

    The stock is up 37.07% over 52 weeks and trades 2.39% below its 50-day average.

    Beta (1Y)0.81
    52-Week Change+37.07%
    1-Month Change+8.43%
    3-Month Change-11.00%
    6-Month Change+11.50%
    5-Year Change+92.37%
    Total Return (1Y)+37.07%
    Total Return (3Y CAGR)+25.96%
    Total Return (5Y CAGR)+17.31%
    Return vs SPY (1Y)+23.11%
    Max Drawdown (1Y)-28.62%
    Max Drawdown (3Y)-63.11%
    Sharpe Ratio (1Y)0.58
    Correlation with SPY (1Y)0.22
    50-Day Average$33.07
    200-Day Average$31.39
    52-Week Range$23.15 to $43.25
    RSI (14 Days)45.9
    Average Volume (20 Days)522.70K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 9.89x current liabilities.

    Current Ratio9.89x
    Quick Ratio9.89x

    Returns and Efficiency

    Return on equity is -69.72% over the last 12 months, against a 5-year average of -42.63%.

    Return on Equity (ROE)-69.72%
    Return on Assets (ROA)-62.61%
    ROE (5Y Average)-42.63%
    ROA (5Y Average)-39.06%
    ROIC (5Y Average)-44.61%

    Scores

    PHVS has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was EUR 0 over the last 12 months.

    RevenueEUR 0
    Operating IncomeEUR -193.47M
    Pretax IncomeEUR -179.08M
    Net IncomeEUR -181.84M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.80% of the EUR 295.06M in total assets.

    Working CapitalEUR 263.55M
    Shareholder EquityEUR 264.97M
    Total AssetsEUR 295.06M
    Total LiabilitiesEUR 30.09M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After EUR 81.40K of capital spending, operating cash flow left EUR -167.62M of free cash flow.

    Operating Cash FlowEUR -167.54M
    Capital ExpendituresEUR 81.40K
    Free Cash FlowEUR -167.62M
    Depreciation and AmortizationEUR 483.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PHVS

    What is PHVS's market cap?

    Pharvaris BV has a market cap of $2.36B.

    How many shares of PHVS are outstanding?

    Pharvaris BV has 70.33M shares outstanding. The count is up 12.96% from a year earlier.

    Does PHVS pay a dividend?

    No. Pharvaris BV does not pay a dividend.